TIGERQ raises € 1 million for market expansion

David Yudovich, CEO of TIGERQ

TIGERQ AB is commercializing services that helps customers to validate the effects of the gene editing tool CRISPR-Cas9 in e.g. drug development. Now, TIGERQ has successfully completed a seed financing round of € 980 000, which will be used to enhance sales activities and product development. The company is a member of SmiLe Incubator in Lund, Sweden.

The discovery of the CRISPR-Cas9 gene editing technology has had a revolutionary impact on the life sciences. The gene editing tool has the potential to transform how we do research, making it faster, more cost effective, and much more accurate. Already today, CRISPR research is accelerating new treatments for cancer and genetic diseases, making the dream of using gene therapy to cure inherited diseases a much closer target.

However, with the new technology there is a need to validate results, and to check the efficiency and genetic outcomes from the DNA editing process. And this is actually the TIGERQ offer: high accuracy and precision analysis services that determine the exact results of both really large and small DNA changes that develop during the CRISPR-Cas9 treatment.

“We are very happy for the interest and support offered by this investment. It´s a great result on a Seed round, for a company with complex technology. Now, we will be able to further drive sales and development efforts to further validate our offer. For us, it is a wonderful opportunity to build on our traction and really demonstrate our potential. We have already demonstrated that we attract customers with flexible and highly-specialized services”, says David Yudovich, CEO of TIGERQ.

TIGERQ is founded on the basis of the research from Lund University by David Yudovich and Jonas Larsson. The company is commercializing its analytic services at the business incubator SmiLe Incubator at Medicon Village, Lund, Sweden.

For more information, please contact: David Yudovich, +46-706422978, David.Yudovich@TIGERQ.com